TARRYTOWN, N.Y.--(BUSINESS WIRE)--PsychoGenics announced today that it has obtained an exclusive license from the University of South Florida to its APP/PS1 double transgenic mice (US Patent No. 5,898,094), co-expressing the M146L presenilin 1(PS1) mutation and the double mutations at K670N/M671L (Swedish mutation) in the amyloid precursor protein (APP).